Table 4.

Aptamer-drug conjugations as cancer-targeted therapeutics

Aptamer names	Aptamer	Target	Drug	Type of cancer	Refs.
sgc8c	DNA	CCRF-CEM cell	Doxorubicin	T-cell acute lymphoblastic leukemia, T-cell ALL	[72]
TLS11a-GC	DNA	LH86 cell	Doxorubicin	Human hepatocellular carcinoma	[73]
MA3	DNA	MUC1 protein	Doxorubicin	Human breast, liver &lung cancer	[74]
HB5	DNA	HER2 protein	Doxorubicin	Breast cancer	[75]
EpDT3 & Scr-EpDT3	RNA	EpCAM protein	Doxorubicin	Retinoblastoma	[76]
E07 & mE07	RNA	EGFR protein	Gemcitabine 5-fluorouracil	Pancreatic cancer	[77, 78]
EpCAM aptamer	RNA	EpCAM protein	Doxorubicin	Colorectal cancer	[79]
TLS11a-GC	DNA	HepG2 cell	Doxorubicin	Hepatocellular carcinoma	[80]
AP-1-M	DNA	CD133 protein	Doxorubicin	Anaplastic thyroid cancer	[81]
AS1411/NucA	DNA	Nucleolin	Doxorubicin/Camptothecin	Breast cancer	[82]
XQ-P3	DNA	PD-L1 protein	Paclitaxel	Treating Triple-Negative Breast Cancer	[83]
AS1411	DNA	Nucleolin	Paclitaxel	Ovarian cancer	[84]
CD117-specific aptamer #1F	DNA	CD117	Methotrexate	Acute myeloid leukemia	[85]
E3	RNA	PC3 (PC-3) cells	Monomethyl auristatin E and F	Prostate cancer	[86]
XQ-2d	DNA	CD71	Monomethyl auristatin E	Uveal melanoma	[87]
P19	RNA	PDAC cell lines	Monomethyl auristatin E and derivative of maytansine 1/	Pancreatic Tumor Cell	[88]
HER2 RNA aptamer	RNA	HER2	Mertansine	Breast Cancer	[89]
S30-T1	DNA	CD33	Doxorubicin	Acute myeloid leukemia	[90]
SQ-2	RNA	ALPPL-2	5-fluoro-2′-deoxyuridine	Pancreatic ductal adenocarcinoma	[91]
APTA12 (Gemcitabine incorporated G-quadruplex aptamer)	DNA	Nucleolin	Doxorubicin/ Gemcitabine	Breast cancer	[92]
APTA12 (Gemcitabine incorporated G-quadruplex aptamer)	DNA	Nucleolin	Gemcitabine	Pancreatic cancer	[93]
G12msi aptamer	DNA	GPC3 protein	Gemcitabine	Hepatocellular carcinoma	[94]
PDGC21-T	DNA	MDA-MB-231	Gemcitabine	Triple-negative breast cancer	[95]
Modified type of AS1411	DNA	Nucleolin	Gemcitabine	Pancreatic cancer	[96]
ThioAp52	DNA	MAGE-A3	Doxorubicin	Breast, oral, pancreatic, and skin cancer	[97]